Hema Now | Episode 8
This week, Jonathan is joined by Marc Hoffman, Associate Professor in Hematologic Malignancies and Cellular Therapeutics at the University of Kansas Medical Center, to discuss novel therapies for B cell malignancies and current challenges in hemato-oncology.
Spotify | Apple | Amazon Music | YouTube | Download MP3 (48 mins)
Marc Hoffman is Associate Professor in Hematologic Malignancies and Cellular Therapeutics at the University of Kansas Medical Center, USA.
Hoffman graduated magna cum laude with a degree in Molecular Biophysics and Biochemistry from Yale University. He went on to earn his medical degree from the University of Pennsylvania, followed by a fellowship in Hematology and Oncology at MD Anderson Cancer Center. Today, he serves as the Medical Director of both Lymphoma and Myeloma at the University of Kansas Cancer Center.
Hoffman’s research and clinical interests focus on lymphoma, myeloma, and hematologic malignancies, with a particular emphasis on improving patient outcomes through innovative treatments and clinical trials. He is also a key member of the Southwest Oncology Group, where he contributes to the Lymphoma Sub-Committee and has been an advocate for advancing lymphoma and myeloma therapies.
- 00:00 – Introduction
- 03:24 – What is molecular biophysics?
- 07:01 – Marc’s journey into hemato-oncology
- 09:36 – Advice to young doctors
- 13:08 – Treatment advances in diffuse large B cell lymphoma
- 19:11 – BRUIN study: pirtobrutinib for B cell malignancies
- 26:15 – Challenges in CAR-T therapy implementation
- 31:31 – A pharmaceutical perspective
- 38:10 – Regulatory insights into clinical trials
- 40:58 – New horizons in hemato-oncology
- 44:26 – Marc’s three wishes for healthcare
